• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Xu Cheryl bought $14,410 worth of shares (5,000 units at $2.88), increasing direct ownership by 46% to 15,816 units (SEC Form 4)

    6/5/25 8:53:09 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SXTP alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    XU CHERYL

    (Last) (First) (Middle)
    C/O 60 DEGREES PHARMACEUTICALS, INC.
    1025 CONNECTICUT AVENUE NW SUITE 1000

    (Street)
    WASHINGTON DC 20036

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    60 DEGREES PHARMACEUTICALS, INC. [ SXTP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/03/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/03/2025 P 3,000 A $2.87 13,816(1) D
    Common Stock 06/03/2025 P 2,000 A $2.9 15,816(1) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Reflects a 1-for-5 reverse stock split effective February 24, 2025, resulting in the reporting person's beneficial ownership being adjusted from 54,078 shares to 10,816 shares. Fractional shares were rounded up to the nearest whole share
    /s/ Cheryl Xu 06/05/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SXTP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SXTP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SXTP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

      New 8-count bottles now available through major retail pharmaciesARAKODA® is the only weekly prophylactic therapy to provide protection against the blood and liver stages of malaria WASHINGTON, June 04, 2025 (GLOBE NEWSWIRE) --  60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the introduction of a new 8-count bottle format for ARAKODA® (tafenoquine). The 8-count bottle format may be suitable for use with patients who are making shorter trips to areas of the world where malaria is endemic. The new format expands the packaging options available to he

      6/4/25 8:56:00 AM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

      25,000 U.S. adults per year claim reimbursement for medical costs associated with babesiosis v. CDC estimates of 2,000A full 45 percent of persistent babesiosis cases include chronic fatigueHealthcare providers treating patients who present with unexplained chronic fatigue may wish to consider babesiosis as a differential diagnosisCompany plans to submit a new drug application (NDA) to FDA in 2026, has two babesiosis clinical trials underway with another anticipated to commence enrollment later this year WASHINGTON, June 03, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new me

      6/3/25 8:49:00 AM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

      Q1 2024 net product revenues increased 55% year-over-year to $163.6 thousand.Gross profit increased 124% to $90.3 thousand. WASHINGTON, May 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the first fiscal quarter of the 2025 year, ended March 31, 2025. Financial Highlights for the Quarter Ended March 31, 2025: Net product revenues increased approximately 55% from $105.7 thousand for the first quarter of 2024 to approximately $163.6 thousand for the first quarter of 2025; the Company credits growth from domes

      5/15/25 4:31:00 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Xu Cheryl bought $14,410 worth of shares (5,000 units at $2.88), increasing direct ownership by 46% to 15,816 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      6/5/25 8:53:09 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Xu Cheryl bought $21,400 worth of shares (13,000 units at $1.65), increasing direct ownership by 32% to 54,078 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      12/18/24 8:35:59 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Dow Geoffrey S bought $89,755 worth of shares (73,951 units at $1.21), increasing direct ownership by 358% to 94,580 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      12/9/24 5:07:49 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTP
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by 60 Degrees Pharmaceuticals Inc.

      SCHEDULE 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

      5/15/25 3:10:40 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by 60 Degrees Pharmaceuticals Inc.

      10-Q - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

      5/15/25 10:07:28 AM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by 60 Degrees Pharmaceuticals Inc.

      SCHEDULE 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

      5/14/25 2:57:24 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Dow Geoffrey S was granted 4,376 shares, increasing direct ownership by 20% to 26,171 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      6/9/25 5:23:56 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Xu Cheryl bought $14,410 worth of shares (5,000 units at $2.88), increasing direct ownership by 46% to 15,816 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      6/5/25 8:53:09 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Dow Geoffrey S

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      1/24/25 4:52:30 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care